Symbol not found

0.00 (0.00%)
Earnings Announcements

Aclaris Therapeutics Reports Q2 Revenue Of $1.5 Mln

Published: 08/03/2022 11:31 GMT
Aclaris Therapeutics Inc (ACRS) - Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update.
Q2 Revenue $1.5 Million.
Qtrly Net Loss per Share, Basic and Diluted $0.31.
Aclaris Therapeutics - Continues to Anticipate Cash, Cash Equivalents As of June 30, 2022 Will Be Sufficient to Fund Operations Through End of 2025.
Q2 Earnings per Share View $-0.36, Revenue View $1.6 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $1.62 Million
Adjusted EPS is expected to be -$0.40

Next Quarter Revenue Guidance is expected to be $1.68 Million
Next Quarter EPS Guidance is expected to be -$0.43

More details on our Analysts Page.